Twelve African markets, and what each requires of a foreign sponsor
In every market below a foreign manufacturer cannot hold its own registration. Each requires a locally incorporated applicant, a local responsible entity and a locally contactable safety point. What differs is the route, the reliance position and the dossier language.
Requirements compared
| Market | Clinical trial route | Reliance / regional | Language | Watch out for |
|---|---|---|---|---|
| South Africa | Predetermined submission cycles, not rolling. Checklist targeted within 3 weeks of receipt; Clinical Trial Committee recommendation targeted within 10 weeks of the submission due date. Additional investigators, sites and protocol amendments approximately 6 weeks. | Formalised reliance procedure using AMA Framework assessments. Parallel submission during the continental process is not accepted. | English. CTD format. | Missing a submission cycle costs a full cycle. Unfamiliar investigational products may be referred to external reviewers, extending timelines. |
| Nigeria | National submission. Route and timeline confirmed per product class. | Confirmed per product. | English. CTD format. | Local representative arrangements and import documentation are the usual friction points. |
| Kenya | National submission with regional routes available for eligible products. | Regional and reliance routes available. Eligibility is product-specific. | English. | Local agent appointment must be in place before submission. |
| Tanzania | National submission. Participates in regional work-sharing arrangements. | Regional work-sharing available for eligible products. | English. | Work-sharing eligibility is not automatic and must be established early. |
| Botswana | National submission with regional work-sharing routes. | Regional work-sharing available for eligible products. | English. | Smaller market: fixed local-presence cost dominates unless clustered with neighbours. |
| Zimbabwe | National submission with regional work-sharing routes. | Regional work-sharing available for eligible products. | English. | Clustering with neighbouring markets usually determines whether entry is economic. |
| Zambia | National submission with regional work-sharing routes. | Regional work-sharing available for eligible products. | English. | Clustering with neighbouring markets usually determines whether entry is economic. |
| Namibia | National submission with regional work-sharing routes. | Regional work-sharing available for eligible products. | English. | Small market: viable mainly as part of a sequenced regional cluster. |
| Ghana | National submission with reliance routes available for eligible products. | Reliance routes available. Eligibility is product-specific. | English. | Local representative required for foreign manufacturers before filing. |
| Uganda | National submission. Participates in regional harmonisation arrangements. | Regional harmonisation routes available for eligible products. | English. | Harmonisation eligibility must be confirmed before sequencing the filing. |
| Mozambique | National submission. Language requirements affect preparation time. | Confirmed per product. | Portuguese. Translation and localisation are on the critical path. | Translation and localisation effort is routinely underestimated in planning. |
| Côte d'Ivoire | National submission. Language requirements affect preparation time. | Confirmed per product. | French. Francophone dossier requirements apply. | Francophone regulatory capacity is scarce and is the usual scheduling constraint. |
Indicative and prepared for orientation. Requirements and pathway eligibility are product-specific and change over time. Confirmed per product as part of an assessment.